Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beam Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 was MXN5,319 Mil.
Beam Therapeutics's quarterly Ending Cash Position
increased
from Sep. 2025 (MXN5,038 Mil) to Dec. 2025 (MXN5,431 Mil) but then
declined
from Dec. 2025 (MXN5,431 Mil) to Mar. 2026 (MXN5,319 Mil).
Beam Therapeutics's annual Ending Cash Position
declined
from Dec. 2023 (MXN7,547 Mil) to Dec. 2024 (MXN6,050 Mil) and
declined
from Dec. 2024 (MXN6,050 Mil) to Dec. 2025 (MXN5,431 Mil).
Beam Therapeutics Ending Cash Position Related Terms
Beam Therapeutics Ending Cash Position Historical Data
* Premium members only.
The historical data trend for Beam Therapeutics's Ending Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beam Therapeutics Ending Cash Position Calculation
Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.
Beam Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as
What does a Ending Cash Position of MXN5,319 Mil mean?
Beam Therapeutics (MEX:BEAM) has a Ending Cash Position of MXN5,319 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Beam Therapeutics and its competitors.
Is Beam Therapeutics' Ending Cash Position too high?
Beam Therapeutics' current Ending Cash Position is MXN5,319 Mil. Overall, Beam Therapeutics has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' Ending Cash Position compare to ELVN and IDYA?
Beam Therapeutics' Ending Cash Position of MXN5,319 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Beam Therapeutics and its competitors. Beam Therapeutics's current Ending Cash Position is MXN5,319 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (MEX:BEAM) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN599.50, compared to a current price of MXN535.00 — trading 10.8% below its estimated fair value. The current Ending Cash Position is MXN5,319 Mil. Beam Therapeutics' overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Beam Therapeutics (MEX:BEAM), the current Ending Cash Position is MXN5,319 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?
Based on GuruFocus' analysis, Beam Therapeutics stock appears to be undervalued.
The current stock price of MXN535.00 is trading 10.8% below its estimated GF Value™ of MXN599.50.
GuruFocus considers Beam Therapeutics to be Modestly Undervalued.
Key valuation signals for MEX:BEAM:
Ending Cash Position: MXN5,319 Mil
GF Value™: MXN599.50 vs. price of MXN535.00 (10.8% below fair value)
No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
70GF Score
Get the complete analysis for MEX:BEAM
Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BEAM has been successfully added to your 
